Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer.

IF 2.2 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2026-04-01 Epub Date: 2026-03-09 DOI:10.1080/14737167.2026.2642646

Mengmeng Liu, Lu Zhong, Mei Dong, Tong Liu

{"title":"Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer.","authors":"Mengmeng Liu, Lu Zhong, Mei Dong, Tong Liu","doi":"10.1080/14737167.2026.2642646","DOIUrl":null,"url":null,"abstract":"Background: This study evaluates the cost-effectiveness of tucatinib plus trastuzumab compared to pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (CRC) from the perspective of healthcare payers in China.Research design and methods: An economic evaluation utilizing a 3-state partitioned survival model assessed the cost-effectiveness of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab.Results: When the price of tucatinib was based on that of lapatinib in China, the estimated cost for tucatinib plus trastuzumab was higher than that of pertuzumab plus trastuzumab (29,130.32 USD vs 12,160.58 USD). The estimated utility was also greater compared to that of pertuzumab plus trastuzumab (2.07 QALYs vs 1.07 QALYs). The ICER was calculated at 17,075.25 USD/QALY, suggesting the tucatinib plus trastuzumab treatment was cost-effective compared to pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic CRC at a WTP threshold of 40,000 USD/ QALY.Conclusions: Tucatinib plus trastuzumab was cost-effective if its price was the same as lapatinib for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic CRC from the perspective of healthcare payers in China. Our exploratory result could provide a reference for clinical application of tucatinib plus trastuzumab when they are correctly interpreted.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"537-547"},"PeriodicalIF":2.2000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2026.2642646","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/9 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study evaluates the cost-effectiveness of tucatinib plus trastuzumab compared to pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (CRC) from the perspective of healthcare payers in China.

Research design and methods: An economic evaluation utilizing a 3-state partitioned survival model assessed the cost-effectiveness of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab.

Results: When the price of tucatinib was based on that of lapatinib in China, the estimated cost for tucatinib plus trastuzumab was higher than that of pertuzumab plus trastuzumab (29,130.32 USD vs 12,160.58 USD). The estimated utility was also greater compared to that of pertuzumab plus trastuzumab (2.07 QALYs vs 1.07 QALYs). The ICER was calculated at 17,075.25 USD/QALY, suggesting the tucatinib plus trastuzumab treatment was cost-effective compared to pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic CRC at a WTP threshold of 40,000 USD/ QALY.

Conclusions: Tucatinib plus trastuzumab was cost-effective if its price was the same as lapatinib for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic CRC from the perspective of healthcare payers in China. Our exploratory result could provide a reference for clinical application of tucatinib plus trastuzumab when they are correctly interpreted.

查看原文本刊更多论文

图卡替尼联合曲妥珠单抗与帕妥珠单抗联合曲妥珠单抗治疗化疗难治性、her2阳性、RAS野生型不可切除或转移性结直肠癌的成本-效果分析

背景：本研究从中国医疗保健支付者的角度评估图卡替尼联合曲妥珠单抗与帕妥珠单抗联合曲妥珠单抗治疗化疗难治性、her2阳性、RAS野生型不可切除或转移性结直肠癌（CRC）的成本-效果。研究设计和方法：利用3状态分区生存模型进行经济评估，评估图卡替尼加曲妥珠单抗与帕妥珠单抗加曲妥珠单抗的成本效益。结果：当图卡替尼在中国的价格以拉帕替尼为基准时，图卡替尼联合曲妥珠单抗的估计成本高于帕妥珠单抗联合曲妥珠单抗（29,130.32美元vs 12,160.58美元）。与帕妥珠单抗加曲妥珠单抗相比，估计的效用也更大（2.07 QALYs vs 1.07 QALYs）。ICER的计算值为17,075.25美元/QALY，表明对于化疗难治性、her2阳性、RAS野生型不可切除或转移性CRC，在WTP阈值为40,000美元/QALY时，与帕妥珠单抗加曲妥珠单抗相比，图卡替尼加曲妥珠单抗治疗更具成本效益。结论：从中国医疗保健支付者的角度来看，如果图卡替尼联合曲妥珠单抗治疗化疗难治性、her2阳性、RAS野生型不可切除或转移性结直肠癌的价格与拉帕替尼相同，则具有成本效益。我们的探索性结果可为正确解读图卡替尼联合曲妥珠单抗的临床应用提供参考。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Pharmacoeconomics & Outcomes Research HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY

CiteScore

4.00

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review. The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.